{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:35:47Z","timestamp":1780619747308,"version":"3.54.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":295,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000625","name":"Great Britain Sasakawa Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000625","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yagi Foundation"},{"name":"JSPS Grant-in-Aid for Scientific Research"},{"name":"British Heart Foundation Centre of Research Excellence","award":["E\/18\/6\/34217"],"award-info":[{"award-number":["E\/18\/6\/34217"]}]},{"name":"Vera Melrose Heart Failure Research Fund"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000625","name":"Great Britain Sasakawa Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the promotion of science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>FINEARTS-HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and mildly reduced or preserved ejection fraction. We examined the effect of finerenone on these events according to their clinical importance using win statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We developed a prespecified hierarchical composite endpoint including the components of the original primary outcome: cardiovascular death (tier 1), total HF hospitalizations (tier 2), and total urgent HF visits (tier 3). For tiers 2 and 3, the number of events was analysed first, followed by the time-to-first event. Because win statistics are affected by the censoring distribution, we assessed the hierarchical composite outcome over a fixed period of 24\u2009months. The 6001 participants analysed were randomized equally to finerenone (n\u2009=\u20093003) or placebo (n\u2009=\u20092998). At 24\u2009months, a total of 825 cardiovascular deaths and worsening HF events were observed in the finerenone group, compared with 1012 events in the placebo group. The win ratio was 1.17 (95% confidence interval [CI] 1.04\u20131.32) (p\u2009=\u20090.010), demonstrating more wins than losses in the finerenone group. The win odds, corresponding to the treatment effect, was 1.05 (95% CI 1.01\u20131.09), and the net benefit, corresponding to the absolute risk difference, was 2.6% (95% CI 0.6\u20134.5%). The win ratio remained above 1.0 from 60\u2009days after randomization and reached a plateau after approximately 12\u2009months. HF hospitalizations contributed more to the overall results than cardiovascular death. The win odds at 12\u2009months was 1.04 (95% CI 1.01\u20131.08), and when adding the Kansas City Cardiomyopathy Questionnaire total symptom score to the hierarchical endpoint as a continuous variable, that increased to 1.07, which is almost identical to the win ratio due to the decrease in ties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Finerenone treatment led to a significant improvement in a composite hierarchical outcome that incorporated cardiovascular death, total HF hospitalizations, and total urgent HF visits, with early onset of benefit.<\/jats:p>\n                    <jats:p>Clinical Trial Registration: ClinicalTrials.gov ID NCT04435626.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3669","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:55:17Z","timestamp":1745960117000},"page":"1459-1471","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Efficacy of Finerenone on Hierarchical Composite Endpoint Analysed Using Win Statistics in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of FINEARTS-HF"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-7574","authenticated-orcid":false,"given":"Toru","family":"Kondo","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair D.","family":"Henderson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development, Bayer AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Bayer plc, Research & Development, Pharmaceuticals , Reading ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schloemer","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals , Whippany, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaviana","family":"Amarante","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[{"name":"General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital, and National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore , Singapore City ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca , Milan ,","place":["Italy"]},{"name":"Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev-Gentofte University Hospital , Hellerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"St Michael's Hospital and University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"von Lewinski","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm Clinical Investigation Centre, CHU , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2026021721460323300_ejhf3669-bib-0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721460323300_ejhf3669-bib-0004","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021721460323300_ejhf3669-bib-0005","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0006","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0007","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/bmj.39136.682083.AE","article-title":"Problems with use of composite end points in cardiovascular trials: Systematic review of randomised controlled trials","volume":"334","author":"Ferreira-Gonzalez","year":"2007","journal-title":"BMJ"},{"key":"2026021721460323300_ejhf3669-bib-0008","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","article-title":"The win ratio approach for composite endpoints: Practical guidance based on previous experience","volume":"41","author":"Redfors","year":"2020","journal-title":"Eur Heart J"},{"key":"2026021721460323300_ejhf3669-bib-0009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J\u2009R Stat Soc Series B Stat Methodol"},{"key":"2026021721460323300_ejhf3669-bib-0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: A new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"2026021721460323300_ejhf3669-bib-0011","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0012","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0013","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721460323300_ejhf3669-bib-0014","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"key":"2026021721460323300_ejhf3669-bib-0015","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): A randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"key":"2026021721460323300_ejhf3669-bib-0016","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026021721460323300_ejhf3669-bib-0017","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"2026021721460323300_ejhf3669-bib-0018","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0019","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","article-title":"Transcatheter repair for patients with tricuspid regurgitation","volume":"388","author":"Sorajja","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jchf.2020.02.010","article-title":"Use of the win ratio in cardiovascular trials","volume":"8","author":"Ferreira","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026021721460323300_ejhf3669-bib-0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020053","article-title":"Cardio\/kidney composite end points: A post hoc analysis of the EMPA-REG OUTCOME trial","volume":"10","author":"Ferreira","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026021721460323300_ejhf3669-bib-0022","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/ejhf.2663","article-title":"Sacubitril\/valsartan versus ramipril for patients with acute myocardial infarction: Win-ratio analysis of the PARADISE-MI trial","volume":"24","author":"Berwanger","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721460323300_ejhf3669-bib-0023","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1681\/ASN.0000000000000243","article-title":"Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026021721460323300_ejhf3669-bib-0024","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721460323300_ejhf3669-bib-0026","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0027","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300042","article-title":"Use of win statistics to analyze outcomes in the DAPA-HF and DELIVER trials","volume":"2","author":"Kondo","year":"2023","journal-title":"NEJM Evid"},{"key":"2026021721460323300_ejhf3669-bib-0028","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-024-02941-8","article-title":"A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials","volume":"30","author":"Kondo","year":"2024","journal-title":"Nat Med"},{"key":"2026021721460323300_ejhf3669-bib-0029","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721460323300_ejhf3669-bib-0030","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721460323300_ejhf3669-bib-0031","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/sim.6010","article-title":"Opportunities and challenges of combined effect measures based on prioritized outcomes","volume":"33","author":"Rauch","year":"2014","journal-title":"Stat Med"},{"key":"2026021721460323300_ejhf3669-bib-0032","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/biostatistics\/kxv032","article-title":"Large sample inference for a win ratio analysis of a composite outcome based on prioritized components","volume":"17","author":"Bebu","year":"2016","journal-title":"Biostatistics"},{"key":"2026021721460323300_ejhf3669-bib-0033","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1177\/0962280216658320","article-title":"An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring","volume":"27","author":"Peron","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"2026021721460323300_ejhf3669-bib-0034","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pst.2251","article-title":"Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes","volume":"22","author":"Dong","year":"2023","journal-title":"Pharm Stat"},{"key":"2026021721460323300_ejhf3669-bib-0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ejhf.2778","article-title":"Use of patient-reported outcomes in heart failure: From clinical trials to routine practice","volume":"25","author":"Savarese","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721460323300_ejhf3669-bib-0036","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jchf.2022.03.003","article-title":"Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF","volume":"10","author":"Butler","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021721460323300_ejhf3669-bib-0037","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jacc.2023.06.047","article-title":"Generalized pairwise comparisons to assess treatment effects: JACC review topic of the week","volume":"82","author":"Verbeeck","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721460323300_ejhf3669-bib-0038","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/pst.1763","article-title":"A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components","volume":"15","author":"Dong","year":"2016","journal-title":"Pharm Stat"},{"key":"2026021721460323300_ejhf3669-bib-0039","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.7895","article-title":"Graphing the win ratio and its components over time","volume":"38","author":"Finkelstein","year":"2019","journal-title":"Stat Med"},{"key":"2026021721460323300_ejhf3669-bib-0040","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1536867X1601600211","article-title":"Reference-based sensitivity analysis via multiple imputation for longitudinal trials with protocol deviation","volume":"16","author":"Cro","year":"2016","journal-title":"Stata J"},{"key":"2026021721460323300_ejhf3669-bib-0041","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/10543406.2013.834911","article-title":"Analysis of longitudinal trials with protocol deviation: A framework for relevant, accessible assumptions, and inference via multiple imputation","volume":"23","author":"Carpenter","year":"2013","journal-title":"J Biopharm Stat"},{"key":"2026021721460323300_ejhf3669-bib-0042","volume-title":"WINS: The R WINS Package","author":"Cui","year":"2024"},{"key":"2026021721460323300_ejhf3669-bib-0043","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021721460323300_ejhf3669-bib-0044","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721460323300_ejhf3669-bib-0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jacc.2024.09.023","article-title":"Effect of finerenone on the KCCQ in patients with HFmrEF\/HFpEF: A prespecified analysis of FINEARTS-HF","volume":"85","author":"Yang","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021721460323300_ejhf3669-bib-0046","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/biomet\/asw026","article-title":"On the win-ratio statistic in clinical trials with multiple types of event","volume":"103","author":"Oakes","year":"2016","journal-title":"Biometrika"},{"key":"2026021721460323300_ejhf3669-bib-0047","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/17407745241259356","article-title":"Defining estimand for the win ratio: Separate the true effect from censoring","volume":"21","author":"Mao","year":"2024","journal-title":"Clin Trials"},{"key":"2026021721460323300_ejhf3669-bib-0048","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ejhf.2853","article-title":"The win ratio method in heart failure trials: Lessons learnt from EMPULSE","volume":"25","author":"Pocock","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/8\/1459\/66813334\/eurjhf_27_8_1459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/8\/1459\/66813334\/eurjhf_27_8_1459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:46:28Z","timestamp":1771382788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/8\/1459\/8468076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4,29]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3669","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"2025-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}